TACC3 and glioblastoma: In conclusion, we strongly emphasize that the prompt identification of the combination between unusual morphology and presence of FGFR3-TACC3 fusion has mainly the practical purpose of identifying a subset of patients with a slightly better outcome than those affected by conventional GBM, IDHwt, and for whom the use of personalized treatment with FGFR kinase inhibitors may be considered.